Human milk sugars with lipid nanoparticle formulation

2023-273 Human milk sugars with lipid nanoparticle formulation

Benefit

The technology’s capacity to significantly enhance RNA delivery promises a substantial improvement in therapeutic outcomes. By fortifying the protection and precision of RNA payloads, it holds the potential to magnify the efficacy of treatments. Additionally, the technology's adeptness in modulating immune responses, attributed to the inclusion of human milk oligosaccharides (HMOs), is a crucial advantage.
This modulation capability not only augments safety profiles by curbing adverse immune reactions often linked with LNPs but also mitigates inflammation, fostering a more tolerable and safer therapeutic experience for patients. Its versatility across various RNA therapies further elevates its significance, opening doors to a wider array of applications and potentially transforming the treatment landscape for diverse diseases. Moreover, the utilization of HMOs from human milk bolsters the therapy's biocompatibility, potentially minimizing the risk of adverse reactions and enhancing patient tolerance, marking a pivotal step towards safer and more effective RNA-based interventions.

Market Application

• Vaccines: Expanding the effectiveness of RNA vaccines beyond COVID-19 by enhancing their delivery and reducing immune reactions could revolutionize vaccine development against a wide array of infectious diseases.

• Gene Therapy: Targeted delivery of RNA could be pivotal in treating genetic disorders by modulating the expression of specific genes, offering potential solutions for conditions currently lacking effective treatments.

• Cancer Therapeutics: RNA therapies have shown promise in cancer treatment by targeting specific tumor-related proteins 1. Enhancing RNA delivery and efficacy while minimizing immune reactions could significantly improve cancer therapies.

• Inflammatory Disorders: The ability of human milk oligosaccharides (HMOs) to inhibit proinflammatory responses could be harnessed for treating diseases characterized by inflammation, such as autoimmune disorders.
   
• Rare Diseases: Many rare diseases stem from dysregulated proteins. This technology offers a platform to tailor RNA therapies for such conditions where specific proteins are upregulated or downregulated.

• Neurological Disorders: RNA therapies have potential applications in neurological disorders where protein dysregulation is a key factor. Improved delivery methods could enhance their efficacy in treating conditions like Alzheimer's or Parkinson's disease.

• Metabolic Disorders: Conditions like diabetes or metabolic syndromes could benefit from RNA therapies targeting proteins involved in metabolic pathways. Enhanced delivery might improve treatment outcomes.

• Personalized Medicine: The adaptability of RNA therapies allows for personalized treatments tailored to an individual's genetic makeup, potentially transforming the landscape of precision medicine.

• Cryopreservation: the same properties that stabilize LNPs for mRNA delivery can also protect cells during the freezing and thawing processes needed to preserve cells at very low temperatures. HMOs can inhibit the formation of ice crystals.

Other Information

IP
Application No.: PCT/US2024/035257
Type: International